DNER and cancer: To pharmacologically target BET proteins, we applied the well-established pan-BETi JQ-1 [27] to treat Huh7 and Hep3B cells, two most sensitive cell lines according to the “The Genomics of Drug Sensitivity in Cancer Project” (Supplementary Fig. S1a).